This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Marin-Oto, M. (Marta); Vicente, E.E. (Eugenio E.); Marin, J.M. (José M.). "Long term management of obstructive sleep apnea and its comorbidities". Multidisciplinary Respiratory Medicine. 14, 2019, 21
Obstructive sleep apnea (OSA) is a worldwide highly prevalent disease associated with systemic consequences,
including excessive sleepiness, impairment of neurocognitive function and daytime performance, including driving
ability. The long-term sequelae of OSA include and increase risk for cardiovascular, cerebrovascular and metabolic
syndrome disorders that ultimately lead to premature death if untreated. To ensure optimal long-term outcomes, the
assessment and management of OSA should be personalized with the involvement of the appropriate specialist. Most
studies have demonstrated inmediate improvement in daytime somnolence and quality of life with CPAP and other
therapies, but the effect of long-term treatment on mortality is still under debate. Currently, the long-term
management of OSA should be based on a) identifying physiological or structural abnormalities that are treatable at
the time of patient evaluation and b) comprehensive lifestyle interventions, especially weight-loss interventions, which
are associated with improvements in OSA severity, cardiometabolic comorbidities, and quality of life. In long-term
management, attention should be paid to the clinical changes related to a potential reoccurrence of OSA symptoms
and it is also necessary to monitor throughout the follow up how the main associated comorbidities evolve.